Updated Jul 16, 2026
Bedrosian Camille L has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $431K.
Camille L. Bedrosian is the Chief Medical Officer at Amylyx Pharmaceuticals, Inc., a company focused on developing therapies for neurodegenerative diseases. She has been involved in multiple SEC filings related to her role, indicating her active participation in the company's operations.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | CRNX | Crinetics Pharmaceuticals, Inc. | A — Grant or award | 5.9K | $0.00 | |
| 2026-03-09 | AMLX | Amylyx Pharmaceuticals, Inc. | A — Grant or award | 96.0K | $0.00 | |
| 2026-03-04 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 6.5K | $14.58 | $94K |
| 2025-12-03 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 6.6K | $14.35 | $94K |
| 2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 12.0K | $14.58 | $176K |
| 2024-12-03 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 5.4K | $5.54 | $30K |
| 2024-10-02 | AMLX | Amylyx Pharmaceuticals, Inc. | S — Open-market sale | 11.4K | $3.20 | $37K |
Camille L. Bedrosian is the Chief Medical Officer at Amylyx Pharmaceuticals, Inc., a company focused on developing therapies for neurodegenerative diseases. She has been involved in multiple SEC filings related to her role, indicating her active participation in the company's operations.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($431K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Bedrosian Camille L profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.